The firm is developing life-enhancing bioprosthetic devices and technologies for patients with debilitating cardiovascular diseases.
Hancock Jaffe Laboratories (Pending:HJLI) intends to sell 1.875 million shares at a midpoint price of $7.00 per share for gross proceeds of $13.1 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing life-enhancing bioprosthetic devices and technologies for patients with debilitating cardiovascular diseases.
Hancock is an early stage medical device firm, and I provide commentary on the IPO in my expanded analysis on Seeking Alpha Marketplace IPO Edge.
